Jump to main content
Jump to site search

Issue 3, 2019
Previous Article Next Article

Effects of n-3 fatty acid supplements on cardiometabolic profiles in hypertensive patients with abdominal obesity in Inner Mongolia: a randomized controlled trial

Author affiliations

Abstract

Daily supplementation with n-3 fatty acid (FA) has been believed to be an adjunct or alternative to drug treatments to reduce blood pressure (BP) and triglyceride (TG) levels in western patients with high risk of cardiovascular disease. The BP-lowering effect of n-3 FA supplements among Chinese hypertensive patients has been reported in our previous 12-week, double-blind, randomized controlled trial (RCT), but the benefits on cardiometabolic profiles among obese Chinese populations are not well known. We therefore used the data from the previous RCT to investigate the effects of marine- and plant-derived n-3 FA supplements on cardiometabolic profiles in middle-aged and elderly Chinese hypertensive patients with abdominal obesity. In total, 108 eligible volunteers from Inner Mongolia, China were randomly assigned to three treatments for 12 weeks: fish oil (FO, n = 35, 2 g day−1 eicosapentaenoic acid + docosahexaenoic acid), flaxseed oil (FLO, n = 39, 2.5 g day−1 α-linolenic acid), and corn oil served as a control (CO, n = 34). BP, blood lipids, waist circumference (WC) and fasting glucose–insulin were measured at baseline and after 12-week intervention by using standard methods. Clustered cardiometabolic risk was expressed as a continuously distributed z-score calculated by standardizing and then summing WC, insulin, glucose, TG, HDL-cholesterol and BP values. The cardiometabolic risk scores were significantly lower in the FO group than in the CO group after the 12-week intervention (−0.41 ± 0.92 vs. 0.02 ± 0.95, p = 0.016), but not in the FLO group (−0.23 ± 1.02 vs. 0.02 ± 0.95, p = 0.109). For individual risk factors, compared with CO, FO significantly decreased LDL-cholesterol (−0.25 ± 0.78 mmol L−1vs. −0.05 ± 0.65 mmol L−1, p = 0.010), ApoB (−012 ± 0.28 mmol L−1vs. −0.03 ± 0.23 mmol L−1, p = 0.036), and WC (−1.58 ± 3.67 cm vs. −0.52 ± 3.27 cm, p = 0.031), whereas no significant difference was found between FLO and CO groups in LDL-cholesterol (p = 0.081), ApoB (p = 0.102) and WC (p = 0.093). The present findings suggest that marine n-3 FA intervention may improve the cardiometabolic traits in this Chinese hypertensive population comorbid with abdominal obesity.

Graphical abstract: Effects of n-3 fatty acid supplements on cardiometabolic profiles in hypertensive patients with abdominal obesity in Inner Mongolia: a randomized controlled trial

Back to tab navigation

Supplementary files

Publication details

The article was received on 29 Aug 2018, accepted on 11 Feb 2019 and first published on 18 Feb 2019


Article type: Paper
DOI: 10.1039/C8FO01707G
Food Funct., 2019,10, 1661-1670

  •   Request permissions

    Effects of n-3 fatty acid supplements on cardiometabolic profiles in hypertensive patients with abdominal obesity in Inner Mongolia: a randomized controlled trial

    B. Yang, M. Shi, Z. Li, L. Shi, A. Wang, X. Guo and D. Li, Food Funct., 2019, 10, 1661
    DOI: 10.1039/C8FO01707G

Search articles by author

Spotlight

Advertisements